Search This Blog

Friday, October 5, 2018

Healthcare jobs growth contributes to lowest unemployment in 49 years


The growth contributed to the unemployment rate falling to 3.7% last month.

The U.S. healthcare sector added about 26,000 jobs last month, including 12,000 associated with hospitals, according to monthly Bureau of Labor Statistics data released Friday.
The growth contributed to the unemployment rate falling from 3.9% in August to 3.7% in September. That’s the lowest unemployment rate since 1969, according to historical BLS data.
Although the report indicated that the economy added 134,000 jobs last month across all sectors, that figure fell well below expectations, falling to the slowest pace in a year, as CNBC reported. But the dampened data could be attributed in part to Hurricane Florence, as Center on Budget and Policy Priorities senior fellow Jared Bernstein wrote in a blog post Friday.
“The decline in unemployment is ‘real,’ meaning it occurred through fewer unemployed persons as opposed to people leaving the labor market,” Bernstein added.
Healthcare employment has increased by more than 300,000 jobs over the year.

HCA’s success over 50 years banks on sticking with the basics


HCA Healthcare’s recipe for success in a complex and technical industry is pretty simple. It comes down to size, deep pockets and unparalleled operational savvy.
The sheer size of Nashville-based HCA, the nation’s largest health system with 178 hospitals and thousands of other facilities, has given it an advantage over others by allowing it to spread the expense of back-office functions, the latest technology, and tasks like billing and purchasing supplies across its vast network, driving efficiency and lowering unit costs.
Size and dominant market share have enabled HCA to negotiate higher prices from health insurers. And lots of cash has allowed it to invest in the buildings, equipment, and clinical research that smaller health systems or stand-alone hospitals don’t necessarily have the capital to do.
Industry experts say that over its 50 years, HCA’s executives have also gotten really good at the day-to-day running of hospitals and understanding changes in the broader healthcare landscape. “It has to do with execution and getting the right people and executing a well-thought-out business plan, and being very entrepreneurial and flexible as the world changes,” co-founder Dr. Thomas Frist Jr. said.

Focused on growth

“It has to do with execution and getting the right people and executing a well-thought-out business plan, and being very entrepreneurial and flexible as the world changes.”
Dr. Thomas Frist Jr.
Co-founder
HCA“It has to do with execution and getting the right people and executing a well-thought-out business plan, and being very entrepreneurial and flexible as the world changes.”
Dr. Thomas Frist Jr.
Co-founder
HCAMark Mosrie
Being big was always the goal. In 1968, Frist, along with his cardiologist father, Dr. Thomas Frist Sr., and Jack Massey, the former owner of fast-food chain KFC, combined their medical expertise with business savvy to build what was then known as the Hospital Corporation of America, which has grown from a 200-bed hospital in Nashville to the behemoth it is today, representing 5%-6% of all U.S. healthcare spending, according to the company.
From the beginning, HCA grew rapidly by buying up hospitals and building new ones as demand surged on the heels of the creation of Medicare and Medicaid. It has had periods characterized by organic growth and others by fast-paced mergers and acquisitions. It has gone private and then back to public at times when valuations were most attractive. And it survived one of the industry’s largest fraud investigations to solidify its reputation as a well-oiled, well-managed corporate machine.
Its net income in 2017 totaled $2.7 billion on revenue of $43.6 billion. That year, HCA’s net patient revenue of $40.1 billion dwarfed that of not-for-profit Kaiser Foundation Hospitals, the next biggest system with net patient revenue of $21.4 billion. Its stock price has grown to nearly $140 per share from $46 five years ago.

Blocking and tackling

HCA’s focus on booming markets where the population is growing, unemployment is low and thus, the demand for healthcare is rising—places like Houston, Nashville, Florida, and Ashville, N.C., where it recently struck a deal to acquire market leader Mission Health—have helped it grow admissions from paying customers even as other hospitals suffer from softer volumes. Its net revenue per adjusted admission has averaged between 2.5% and 2.7% over the past several years, driven by the local markets’ growing population and aging seniors’ demand for services, said CEO R. Milton Johnson, who is retiring at the end of this year to be succeeded by HCA President and Chief Operating Officer Sam Hazen.
When expanding into new territories, HCA eyes areas where it will dominate in terms of market share, which it can leverage into negotiating power to secure better rates from insurers.
“They want to be the No. 1 or No. 2 player in every market they go into,” said Brian Tanquilut, a Nashville-based equity analyst at investment firm Jefferies & Co. “They are very methodical, and they stick to a strategic playbook.”
That approach also means HCA generally steers clear of communities with less-than-favorable payer mixes.
“They tend not to open hospitals in impoverished neighborhoods and in states that pay poorly,” said Scott Phillips, managing director for Healthcare Management Partners.
Before 2017, HCA hadn’t entered a new market since 2003. In the years prior it invested in facilities, doctors and capabilities in areas where it already operated, taking share from its competitors. In Nashville, for instance, HCA expanded its pediatric services and is siphoning customers away from the renowned Monroe Carell Jr. Children’s Hospital at Vanderbilt, which has the higher prices typical of academic systems, Tanquilut said.
Under the direction of Johnson and Hazen, HCA has aggressively added outpatient clinics, urgent-care centers, free-standing emergency departments and ambulatory surgery centers to complement its hospitals. The company ended 2017 with 72 free-standing EDs and 123 urgent-care centers with plans to add more. Hazen said the company now has roughly 2,000 facilities providing outpatient care, which makes up 38% of HCA’s revenue.
“They were buyers of outpatient businesses and imaging clinics at the right time of the cycle, and now with the inpatient hospital being out of favor, they’ve been able to take advantage of the market,” said Nephron Research analyst Joshua Raskin.
He noted that HCA also empowers its hospital leaders with the tools necessary to drive change in their markets, such as the technologies needed to understand what staffing levels are necessary and what patient volumes will look like.
Those investments were possible because HCA generates a lot cash. Through its internal revenue-cycle management business, a service it also sells to other hospitals, HCA is adept at collecting payment from patients for services and making sure health plans pay up, Tanquilut said. In 2018, HCA will have generated $2.4 billion in free cash flows after investments, while other hospitals are pulling back on investments to pay off debt.
“They are operationally savvy,” said Paul Keckley, an industry analyst in Nashville. HCA leadership understands where to build its hospitals, how many beds to allot, how to staff and how to buy supplies. And their financial, operational and clinical decisions have been backed by hard data that HCA collected before it was necessary for compliance standards, Keckley said.
Importantly, HCA’s executives and managers are trained to demand and use that information, and are held accountable for producing results, said Dr. Mike Schatzlein, former CEO of Ascension Health’s St. Thomas Health who has also worked for HCA-owned hospitals. “Their operators know their numbers, and so they can react in real time and operate efficiently,” he said. “If you operate efficiently, that means you have reduced variation, waste and rework—and that results in higher quality.”
Analytics also gives HCA an edge in setting prices.
“They are the absolute leaders in maintaining discipline with their cost structure, but they also have world-class analytics to know where and when they can successfully raise prices, down to the smallest unit,” Paul Hughes-Cromwick, co-director of sustainable health spending strategies for consultancy Altarum, said in an email.
HCA’s aggressive pricing, enabled by its market share and patient volume, is a major factor in its financial success. Researchers have found that HCA’s negotiating power with insurers allows it to set high prices for its healthcare services. The high cost of healthcare in the U.S. is in part attributed to high prices, not the actual cost of services, experts say.
“They’re out to maximize profit, and one of the ways you can do it is by raising prices,” said Gerard Anderson, a health policy professor at Johns Hopkins University who has studied HCA’s prices.
Anderson and Johns Hopkins associate professor Ge Bai’s 2015 Health Affairs study found that HCA owned more than one-quarter of the top 50 U.S. hospitals with the highest ratio of charges to Medicare-allowable costs in 2012. Those 50 hospitals marked up charges by 1,000% on average. For-profit competitor Community Health Systems owned more than half of the hospitals. While charges don’t reflect the payment rates that most patients pay, uninsured patients often do end up paying full charges, Anderson said. About 28 million people were uninsured in 2016.
In another Health Affairs study published this month, Anderson and Bai found that the 20 hospitals in Florida with the highest prices for auto, workers compensation, liability and travel insurers in 2016 were all owned by HCA. Oftentimes, these nontraditional insurers pay for consumers’ medical expenses when an accident occurs, for example. But such insurers are smaller than giant HMO and PPO payers, and so have less negotiating power with big health systems.
The 20 HCA hospitals with the highest prices set them at 7.8 to 14.1 times the rate of Medicare, with a median price twice that of the other 124 hospitals operating in Florida that year, researchers found. Those 20 HCA hospitals received about a quarter of their commercial net revenue from such insurers—twice that of other payers—despite treating a small number of patients covered by them. The stakes are high for patients, because policies such as an auto insurance plan often have low coverage limits and high out-of-pocket spending.
HCA’s prices for HMOs and PPOs were largely in line with the other hospitals in Florida, the researchers said. The 20 highest-priced hospitals set prices at 1.7 to 4.1 times Medicare rates.
An analysis using the Modern Healthcare Metrics database, which relies on Medicare cost reports, found that HCA hospitals were docked $38.3 million in readmissions penalties and $9.1 million in value-based purchasing penalties in 2017.

A learning system

“It didn’t take one hospital 64 years to get these data. It took 43 hospitals 18 months.”
Dr. Jonathan Perlin
Chief medical officer
HCA Healthcare“It didn’t take one hospital 64 years to get these data. It took 43 hospitals 18 months.”
Dr. Jonathan Perlin
Chief medical officer
HCA Healthcare
HCA has leveraged its scale to solve big problems in clinical care and produce better outcomes for patients. The health system stores information from its 32 million patient visits per year in a clinical data warehouse and has a dedicated team of 300 professionals who find ways to use that data to improve best practices, said Dr. Jonathan Perlin, HCA’s chief medical officer. Some of HCA’s research into best practices have led to changes in clinical processes across the nation, he said.
In one case, HCA studied the difference in the rate of newborns going to the neonatal intensive-care unit after an early elective delivery. Over decades, the term of a mother’s pregnancy had been shortened from the normal 39 weeks because of convenience, but it wasn’t known if shorter terms meant higher risk of newborn complications.
Because so many babies are delivered at HCA hospitals, the health system was in a position to find out. It studied 18,000 births over 90 days and found that the risk for complications requiring a baby to go to the NICU was four times greater when delivered electively at 37 weeks and more than two times greater at 38 weeks than delivering at full term.
Similarly, HCA used its patient data to test the best approaches to preventing MRSA and other hospital-acquired infections over 18 months. The chain managed to reduce MRSA rates by 37% and cut all potentially life-threatening blood stream infections in the ICU by 44%. The study changed practice in the U.S. and worldwide, Perlin said.
“This is really what a learning health system can allow, which was research conducted during the course of normal operations by normal care providers at speed and at scale to definitively answer a question that’s important for the patients we’re privileged to treat,” Perlin said. “It didn’t take one hospital 64 years to get these data. It took 43 hospitals 18 months.”
HCA’s track record isn’t spotless. Its ill-fated 1994 merger with Louisville, Ky.-based Columbia Hospital Corp. ended with one of the largest Medicare fraud settlements when Rick Scott, who is now the governor of Florida and running for the U.S. Senate, was at the helm of the merged company. The investigation and a roughly $2 billion settlement were an embarrassment to HCA’s culture and tarnished its reputation at the time. It is largely now considered a distant memory by many in the industry.
The hospital system has also been criticized for refusing to treat patients who came to the emergency department with nonurgent conditions unless they paid upfront, a strategy that helped reduce ED costs and overcrowding. A 2012 New York Times story also accused several HCA Florida hospitals of performing unnecessary cardiac procedures to grow profits.
Critics might take issue with HCA’s for-profit model, Keckley said. HCA doesn’t take many risks, and it doesn’t chase trends. It makes decisions about clinical programs based on potential payoff, and will leave a market if it’s not profitable enough, Keckley said.
“They don’t want to be on the bleeding edge of anything,” he said. But “it’s an interesting model and you have to respect their success. It’s their efficiency and their data-driven approach to looking at opportunity that I think is exceptional bar none.”

Moody’s picks 5 early winners in biosimilar market


  • While biosimilars have yet to take off in the U.S., top credit rating agency Moody’s remains optimistic of the future market opportunity for the biologic copycats, calling the competition “a rising headwind for branded pharmaceutical companies” in an Oct. 4 report.
  • The agency’s analysis highlighted five pharmaceutical giants that stand to gain the most from biosimilars, as well as four companies at the highest risk from these drugs.
  • In Europe, annual sales erosion is expected at eat between 25% and 30% out of branded sales, Moody’s found, while the U.S. remains “slow to date” in adoption.

Eight of the top 10 selling drugs in the world were biologics in 2017, creating a huge market opportunity for biosimilars. Moody’s analysts are paying attention to how the still-developing area could affect the bottom lines of the industry’s biggest players.
“Over the next year or so, as biosimilars gain traction globally, several branded pharmaceutical companies will face declining sales of important blockbuster drugs,” Michael Levesque, a Moody’s senior vice president and lead author of the report, said in an Oct. 4 statement.
“Biosimilars have seen strong uptake in Europe and this trend will accelerate as the biosimilar market there continues to develop, with more drugs approved and launched.”

The winners

The report selected Pfizer, Biogen, Novartis, Amgen and Mylan as the initial leading biosimilar companies by sales, with a slate of already launched biosimilars and others in development between them.
Moody’s expects Pfizer to post $700 million in biosimilar revenues for 2018, growing to $1.5 billion in 2020.
Biogen, through its share of a joint venture with Samsung Bioepis, is poised to be runner-up to Pfizer, with $550 million in expected 2018 sales from biosimilars and $1 billion by 2020.
For 2020, Moody’s estimated Novartis’ Sandoz unit to log $750 million in biosimilar revenue, and Amgen and Mylan to reach $500 million each.

Companies most at risk from biosimilars

The report also concluded Roche, Amgen, AbbVie and Johnson & Johnson will likely face declining sales in the next 12 to 18 months for key products dinged by biosimilar competition.
Nearly half of Roche’s global sales come from three cancer biologics: Rituxan (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab). The first two are now facing European biosimilars and Moody’s deemed it likely they will also see U.S. copycats by 2019.
Other at-risk drugs include Amgen’s Neulasta (pegfilgrastim) and Epogen (epoetin alfa) — which combine to make up about 25% of total sales for the company —​ AbbVie’s Humira (adalimumab) and J&J’s Remicade (infliximab).

Shifting regulatory landscape

Amgen is in a unique position, standing both to gain and to lose from biosimilar uptake. Copycat competition could take a bite out of Amgen’s biologic sales, even as the California biotech seeks to do the same to some of its large-cap peers.
This fits with a notable distinction between the markets for biosimilars and generics: large pharma has been on both sides of the biosimilar game, as Richard Mortimer, a managing principal at the Analysis Group who specializes in health economics, recently noted in an Oct. 4 talk on the subject.
With generics, the pharma industry largely stood united against companies that focused exclusively on knockoff copies. Biosimilars, however, have so far led to some splits in the ranks, as the high-profile legal battles between Novartis and Amgen, and Pfizer and J&J have shown.
Mortimer predicted drugmakers will be more active in promoting biosimilars than generics. He also expects to see more brand-brand competition between biologics and their copycats, partially due to the absence — so far — of any fully interchangeable biosimilars in the U.S.
Moody’s found the U.S. regulatory framework to still be evolving, but was optimistic that biosimilars will be helped by future efforts from the Food and Drug Administration and from the White House’s drug pricing blueprint.

Retrophin to Present Long-Term Phase 2 Sparsentan Data at Kidney Meeting


Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data examining the long-term effects of sparsentan in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2018. The Company will present an 84-week analysis of the open-label extension portion of the Phase 2 DUET Study, as well as preclinical findings demonstrating that treatment with sparsentan provides nephroprotection in an autosomal mouse model of Alport syndrome. FSGS and Alport Syndrome are rare, progressive kidney disorders that often lead to end-stage renal disease (ESRD). ASN Kidney Week 2018 is being held October 23–28, 2018, in San Diego, CA.
Oral Presentation:
Long-term Effects of Sparsentan, a Dual Angiotensin and Endothelin Receptor Antagonist in Primary Focal Segmental Glomerulosclerosis (FSGS): Interim 84-Week Analysis of the DUET Trial
Abstract Program #: FR-OR087 
Session: Glomerular Diseases: Clinical, Outcomes, and Trials
Location: Room 24A, San Diego Convention Center
Date & Time: Friday, October 26, 2018, 6:18 p.m. – 6:30 p.m. PT
Poster Presentation:
Sparsentan, a Dual Angiotensin II Type 1 (AT1) and Endothelin Type A (ETA) Receptor Antagonist, Prevents Renal Disease in COL4A3 -/- Autosomal Alport Mice
Poster #: FR-PO624
Session: Genetic Diseases of the Kidney Non-Cystic II
Location: Exhibit Hall C, San Diego Convention Center
Date & Time: Friday, October 26, 2018, 10:00 a.m. – 12:00 p.m. PT

AbbVie Gets Health Canada Approval of Orilissa for Endometriosis Pain


AbbVie and Neurocrine Biosciences said Friday that Health Canada approved Orilissa for the treatment of moderate to severe pain associated with endometriosis.
The companies said Orilissa is an orally administered treatment for endometriosis, affects up to one in 10 women of reproductive age in Canada.
“Endometriosis causes a significant impact on the quality of life of women because of the debilitating and incapacitating pain. Women living with endometriosis can be sidelined by this disease,” says Dr. Nicholas A. Leyland, Chair of the Department of Obstetrics and Gynaecology at McMaster University. “Since there is no cure, the goal of treatment is to alleviate the symptoms and improve a woman’s quality of life.” He said Orilissa offer a new option for treating the condition.
The companies said Orilissa is supported by data from two replicate Phase 3 studies, which evaluated nearly 1,700 women.
Orilissa is expected to be available in Canadian retail pharmacies in early November.

FDA Approves Expanded Use of Merck’s Gardasil 9


The U.S. Food and Drug Administration said Friday they granted approval to a supplemental application for Gardasil 9, which expands the approved use of the vaccine to include women and men aged 27 through 45 years.
Gardasil 9 prevents certain cancers and diseases caused by the nine human papillomavirus, or HPV, types covered by the vaccine.
The FDA granted approval to Merck, Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc. (MRK).
According to the Centers for Disease Control and Prevention, every year about 14 million Americans become infected with HPV; about 12,000 women are diagnosed with and about 4,000 women die from cervical cancer caused by certain HPV viruses. Additionally, HPV viruses are associated with several other forms of cancer affecting men and women.

Gambling: ‘A banking app helped me beat my addiction’


Tens of thousands of people have signed up to a new service from two mobile-only banks designed to help problem gamblers. One former addict says this “gambling block”, available on the banks’ apps, helped him beat his addiction.
“I’d be setting my alarm to wake up at 4am to do a first bet,” says Danny Cheetham, who began placing bets in his early 20s.
“I’d plan my route to work so I could call in to a bookies which opened early for commuters.”
Danny, who is now 29, found himself betting in bookies, on slot machines and online. He gambled a lot on football, which he doesn’t even like.
He began relying on overtime from work and on payday loans. In the course of eight years, Danny, who’s from Stockport, estimates he lost more than £50,000.
He sunk into depression and moved in with his dad as he could not afford to pay rent.
It was the death of his mum Christine in 2015 that he says was the turning point for him – but he was not able to kick his habit until he signed up to a gambling block with his bank, Monzo. The so-called challenger bank is a mobile-only version of a traditional bank.
Once the block is activated by the customer, it can spot any transaction that person might try to make with bookmakers – either online or in a shop – by using merchant category codes. It instantly stops the transaction from happening, before any money has left that customer’s account.
If a customer is tempted to place a bet in the heat of the moment, there is a 48-hour cooling-off period before the block is switched off. There is also a daily limit on cash withdrawals.
Presentational grey line

Gambling addiction: The facts

  • 430,000 problem gamblers in Britain
  • Two million people “at risk”
  • Harm can include higher levels of physical and mental illness, debt problems, relationship breakdown and, in some cases, criminality
Presentational grey line
Monzo CEO Tom Blomfield says the block was introduced because customers asked for it.
“We have a team of people who work with vulnerable customers and they were getting this feedback quite often” he says.
More than 25,000 customers have signed up to the bank’s block since it went live in June.
“Not all of those were problem gamblers [but] about 8,000 people did have a history of gambling,” says Mr Blomfield.
“We’ve… seen a 70% decline in their gambling transactions so [it’s made] a really big impact.”
Another challenger bank, Starling, is offering a similar type of block. It’s gained 20,000 users since its launch in June.
Danny Cheetham working for Gaydio radio station in ManchesterImage copyrightDANNY CHEETHAM
Image captionDanny had a promising career as a radio DJ before his addiction took hold and derailed his plans
The Royal College of Psychiatrists is calling on the big five high street banks – Lloyds, Santander, HSBC, RBS Group and Barclays – to offer the same type of service.
Doctor Henrietta Bowden-Jones told BBC Radio 4’s Money Box: “If you are unable to access funds, this type of gambling block can save people’s homes and their families.”
The banks say protecting vulnerable customers is a priority and they are always looking at new ways to do that.
The Gambling Commission is talking to financial institutions about how to improve protection for problem gamblers.
Danny Cheetham
Image captionDanny says he lost more than £50,000 but has now beaten his addiction and hopes to be debt-free within a year
Three years on from taking his first steps to beat his gambling addiction, Danny says he is happy.
“And I’ve actually got money in the bank which I never thought I’d have,” he says.
“I’m well on target to being debt-free by my 30th birthday, which is my next one, and I just don’t feel depressed or helpless like I used to.”
He says he can now think about his future and – although he will have a bad credit file for up to six years – he says this will give him time to save for a deposit for his own place.
“I just don’t feel like it’s an endless battle any more.”
You can hear more on BBC Radio 4’s Money Box programme on Saturday at 12:00 BST or listen again here.
If you’re worried you might have a problem with gambling or know someone who does you can get help here.